Associated Papers
Quantification of plasma mutant calreticulin for diagnosis and therapeutic response assessment of peginterferon-α in myeloproliferative neoplasms: A proof-of-concept study.
Tian J et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2026
Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort.
Lu X et al.
Biomedicines, 2026
A rare CALR exon 9 mutation p.E379Vfs*53 in AYA generation exhibits gain-of-function nature and can induce essential thrombocythemia; a case report.
Nagaharu K et al.
Hematology (amsterdam, Netherlands), 2025
A Comprehensive Guide to Achieving New York State Clinical Laboratory Evaluation Program Approval for Next-Generation Sequencing Assays.
Galbo PM et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes.
Hiitola E et al.
Science Advances, 2025
ELC52: a novel megakaryocytic leukemia cell line with a CALR type 1 mutation.
Yamamoto Y et al.
Leukemia, 2025
Case Report: A novel t(15;17)(q24;q11.2) translocation involving NF1::SCAMP5 fusion in a patient with myeloproliferative neoplasms.
Chang Y et al.
Frontiers in Oncology, 2025
JAK/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders.
Djidjik R et al.
Frontiers in Immunology, 2025
Genetic architecture of telomere length in 462,666 UK Biobank whole-genome sequences.
Burren OS et al.
Nature Genetics, 2024
High-resolution melting assay for rapid, simultaneous detection of JAK2, MPL and CALR variants.
Sande CM et al.
Journal of Clinical Pathology, 2024
Initiating-clone analysis in patients with acute myeloid leukemia secondary to essential thrombocythemia.
Ushijima Y et al.
Scientific Reports, 2024
Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119.
Köhnke T et al.
Blood Cancer Discovery, 2024
Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.
Kandarpa M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Outcome heterogeneity of TP53-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation.
Pasca S et al.
Haematologica, 2024
Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.
Narlı Özdemir Z et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology, 2024
Acute myeloid leukemia with a novel AKAP9::PDGFRA fusion transformed from essential thrombocythemia: A case report and mini review.
Sahin Y et al.
Leukemia Research Reports, 2024
COMPASS: joint copy number and mutation phylogeny reconstruction from amplicon single-cell sequencing data.
Sollier E et al.
Nature Communications, 2023
Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations.
Guijarro-Hernández A et al.
Bmc Genomic Data, 2023
Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.
Garrote M et al.
Cancers, 2023
Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1 CALR-Mutated MPN.
Wang YH et al.
International Journal of Molecular Sciences, 2023
ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms.
Shi Z et al.
Haematologica, 2023
Clinical and molecular characteristics of forty Chinese children with essential thrombocythemia: A single-center, retrospective analysis.
Zhang L et al.
British Journal of Haematology, 2023
Advances in molecular evaluation of myeloproliferative neoplasms.
Li N et al.
Seminars in Diagnostic Pathology, 2023
Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.
Foßelteder J et al.
Leukemia, 2023
Structural and Dynamic Differences between Calreticulin Mutants Associated with Essential Thrombocythemia.
Radjasandirane R et al.
Biomolecules, 2023
Case report: Application of targeted NGS for the detection of non-canonical driver variants in MPN.
Zhang J et al.
Frontiers in Genetics, 2023
Expression properties, structural features and functional analysis of CALR E381A in MPN patients.
Xu K et al.
American Journal of Translational Research, 2023
Leukemic conversion involving RAS mutations of type 1 CALR-mutated primary myelofibrosis in a patient treated for HCV cirrhosis: a case report.
Gurban P et al.
Frontiers in Oncology, 2023
Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.
Abdelghani M et al.
Journal of Clinical Laboratory Analysis, 2022
CHST15 gene germline mutation is associated with the development of familial myeloproliferative neoplasms and higher transformation risk.
Chen Y et al.
Cell Death & Disease, 2022
In utero origin of myelofibrosis presenting in adult monozygotic twins.
Sousos N et al.
Nature Medicine, 2022
Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results.
Kahraman CY et al.
The Eurasian Journal of Medicine, 2022
Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.
Wiriyaukaradecha K et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2022
How I Diagnose Primary Myelofibrosis.
Prakash S et al.
American Journal of Clinical Pathology, 2022
Pathogenic "germline" variants associated with myeloproliferative disorders in apparently normal individuals: Inherited or acquired genetic alterations?
Veitia RA et al.
Clinical Genetics, 2022
Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel.
Tan J et al.
Bmc Medical Genomics, 2022
CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.
Olschok K et al.
Stem Cell Reports, 2021
Mapping human calreticulin regions important for structural stability.
Čiplys E et al.
Biochimica Et Biophysica Acta. Proteins and Proteomics, 2021
A Comparison of Two Molecular Methods for Detecting CALR Mutations in Myeloproliferative Neoplasms.
Chan TH et al.
Clinical Laboratory, 2021
Mechanism of mutant calreticulin-mediated activation of the thrombopoietin receptor in cancers.
Venkatesan A et al.
The Journal of Cell Biology, 2021
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Stockklausner C et al.
Annals of Hematology, 2021
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.
Balliu M et al.
Blood Advances, 2021
A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina.
Kurtovic-Kozaric A et al.
Acta Medica Academica, 2021
The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.
Belčič Mikič T et al.
International Journal of Molecular Sciences, 2021
Cardiotoxicity of Novel Targeted Hematological Therapies.
Giudice V et al.
Life (basel, Switzerland), 2020
Primary myelofibrosis with concurrent CALR and MPL mutations: A case report.
Zhou FP et al.
World Journal of Clinical Cases, 2020
Myelofibrosis biology and contemporary management.
Gangat N et al.
British Journal of Haematology, 2020